CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to REGN

Cemiplimab 350 MG Intravenous Solution

Phase 2
Regeneron Pharmaceuticals, Inc. (REGN)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Clear Cell Renal Cell Carcinoma

View Full Landscape
Drug Information

Target Indication

Clear Cell Renal Cell Carcinoma

Clinical Trial

NCT07223541

Last updated: 8/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.